Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 24;30(4):906–921. doi: 10.1038/s41418-022-01108-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — A–E M-MDSCs differentiated from WT BM cells and activated in the presence (M-MDSC-Gal-7) or absence (M-MDSC-C) of rGal-7 were injected weekly in Lgals7^−/− mice, during the two-stage carcinogenesis protocol. A Tumor growth was weekly monitored and scored. Average tumor number in each experimental group (left panel; mean ± SEM; 3 independent experiments) and representative images of mouse shaved backs and H&E of papillomas (right panel) are shown. B Frequency of papilloma-free mice. C Total tumor number in each experimental group (n = 6 animals per group, from one representative experiment are shown). D, E Characterization of tumor infiltrate in papillomas from Lgals7^−/− animals injected with M-MDSC-C or M-MDSC-Gal-7. Determination of M-MDSCs and PMN-MDSCs frequencies and of M-/PMN-MDSC ratio (D), and assessment of CD8⁺ and CD4⁺CD25⁺Foxp3⁺ cell frequencies, as well as CD8⁺/CD4⁺CD25⁺ Foxp3⁺ ratio (E) are shown (mean ± SEM; 3 independent experiments). F–J Tg46 mice were treated weekly with anti-DR5 mAb or with isotype control mAb beginning from the first month of the carcinogenesis protocol (n = 3, 5 and 6 animals per group; 3 independent experiments). F Tumor growth was weekly monitored and scored. Curves corresponding to tumor progression of individual animals (left panels) and representative images of one animal from each experimental group and H&E of papillomas (right panel) are shown. G Frequency of papilloma-free mice is shown. H Total tumor number in each experimental group (n = 6 animals per group, from one representative experiment are shown). I, J Characterization of tumor infiltrate in papillomas from Tg46 animals treated with anti-DR5 mAb or with isotype control. Frequencies of M-MDSCs and PMN-MDSCs, and M-/PMN-MDSC ratio (I) and determination of the frequencies of CD8⁺ and CD4⁺ CD25⁺ Foxp3⁺ cells, and CD8⁺/ CD4⁺ CD25⁺ Foxp3⁺ ratio (J) are shown (mean ± SEM; 3 independent experiments). In panels A and F p values correspond to the end point of the experiment.